DiagnoCure joins the OTCQX Marketplace and S&P Corporation Records Listing

Apr 02, 2013, 07:00 ET from DiagnoCure inc.

QUEBEC CITY, April 2, 2013 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR) (OTCQX: DGCRF), today announced that the Company's stock is now trading on OTCQX International under the symbol "DGCRF". OTCQX is the best U.S. OTC marketplace, providing an opportunity to significantly broaden and enhance DiagnoCure's access and exposure within the U.S. market. The OTCQX marketplace has earned an exemplary reputation for providing U.S. investors with improved liquidity, transparency, superior information, and easy access through their U.S. regulated broker dealers. It is also recognized within the industry for maintaining rigid quotation standards for companies that trade there. Investors can find current financial disclosures and Real-Time Level 2 quotes for DiagnoCure on www.otcmarkets.com.

In addition, DiagnoCure announced today that its company information would be made available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of DiagnoCure will be published in the Daily News Section of Standard & Poors' Corporation Records, a recognized securities manual for secondary trading in up to 38 states under the Blue Sky Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors. The company information about DiagnoCure to be made available through this program includes an in-depth description of the DiagnoCure's business operations, share price, dividend history, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

Canaccord Genuity will be the market maker of DiagnoCure's stock. Canaccord Genuity is a global, full-service investment bank focused on growth companies and is one of the largest market maker in the United States.

Dorsey & Whitney LLP will serve as DiagnoCure's Principal American Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements and U.S. securities laws.

"Trading on OTCQX International will provide enhanced access to U.S. investors and the ability for DiagnoCure to diversify its shareholder base," said Chantal Miklosi, Chief Financial Officer of DiagnoCure. "We believe that trading on the OTCQX marketplace is in the best interest of shareholders and will enable the Company to enhance the market liquidity of DiagnoCure shares."

About DiagnoCure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. (NASDAQ: HOLX) operating as Hologic Gen-Probe, for the development and commercialization of a prostate cancer test using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic Gen-Probe's PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States. For more information, visit www.diagnocure.com.

Forward‐looking statements

This release contains "forward‐looking statements," within the meaning of applicable United States and Canadian securities laws, that involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expected. By their very nature, forward‐looking statements are based on expectations and hypotheses and also involve risks and uncertainties, known and unknown, many of which are beyond DiagnoCure's control. As a result, investors are cautioned not to place undue reliance on these forward‐looking statements. Such forward-looking statements include the outcome of research and development projects, clinical studies, future revenues, the benefits of being quoted on the OTCQX and the improved liquidity of the Company's shares when traded on the OTCQX and are based on management expectations. In addition, the reader is referred to the applicable general risks and uncertainties described in DiagnoCure's most recent Annual Information Form under the heading "Risk Factors". DiagnoCure undertakes no obligation to publicly update or revise any forward‐looking statements contained herein unless required by the applicable securities laws and regulations.

SOURCE DiagnoCure inc.